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Abstract
SMALL MOLECULES BINDING TO SERPINS
By Junaid Haider Afridi, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University
Virginia Commonwealth University, 2006
Dr. Umesh Desai, Associate Professor, Medicinal Chemistry
Serpins are a unique breed of proteins due to their enzymatic
mechanism. Two systems were closely monitored during fluorescent binding
studies, the ACT-CHY along with the AT:TRY interaction. Four different
conformational variants of each system were studied including the native,
cleaved, latent and complex forms. Three different fluorescent dyes were used
to identify the conformations including ANS, TNS, and bis-ANS. SI studies and
protease assays utilizing both Suc-AAPF-pNA and L-BAPNA were instrumental
in determining conformations along with gel electrophoresis studies. The
hydrophobic dyes bound to the different serpins with varying KDand AFmax
due to structural variations among the conformers and the complex. Both TNS
and bis-ANS gave higher AFmax values than ANS. Bis-ANS gave significantly
higher AFmax values for the ACT:CHY than the other conformations, while also
exhibiting relatively low KDvalue. KDvalues for the bis-ANS complexes are
relatively low when compared to other fluorophores. Bis-ANS is more specific
for the AT system than either TNS or ANS. Bis-ANS displays a AFmax of 36
fold for the ACT:CHY complex, while TNS displays a 27 fold increase for

AT:TRY system. Modulation studies using bis-ANS to alter the kinetics of latent
ACT formation proved unsuccessful, suggesting that fluorescent dyes have
little, if any effect on serpin variant formation.

Chapter 1: Introduction
Serpins were first identified as a family of molecules by Hunt and
coworkers in 1980, after noticing a primary sequence identity of -30% among
human al-antitrypsin, human antithrombin, and chicken egg white ovalbumin.ls2
Later, antitrypsin and antithrombin, along with a handful of other similar
molecules were found to inhibit proteases containing serine as a catalytic
residue, and hence the name ~ i n potease
e
bhibitors (serpins). Many other
proteins have now been added to this list, which continues to grow, although
many are not inhibitors of serine proteases3
Today nearly 500 serpins across all species are known to exist. All
proteins classified as serpins have a common tertiary structural fold consisting of
3 P-sheets and 8-9 a-helices. Outside of these conserved structural domains the
sequence variability is quite large. Most serpins have a molecular weight ranging
from 40 to about 65 kDa, while the largest known serpin, C1 inhibitor, has a
molecular weight of about 105 k ~ a Some
. ~ of the unusual serpins include
cysteine protease inhibitors, such as squamos cell carcinoma antigen I, and
noninhibitory serpins, such as egg white ovalbumin and angioten~in.~
The 500 or so serpins have been classified by the HUGO Gene
Nomenclature Committee and placed into sixteen different serpin clades based

on their phylogenetic associations. The clades are designated by letters ranging
from A through P . ~

Table 1. Physiological Role of Serpins in the Human ~
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Figure 1: Taken from ~ettins.' Four stereo views of a,-antitrypsin, a prototype serpin molecule. The RCL
is known as the reactive center loop, and can be seen at the top of the molecule while h denotes a helix,
and s denotes p sheet. The important residues are the RCL in yellow, and p sheet C in red.

Human serpins are located on 10 different chromosomes, although a
majority of them are located in three clusters. It is interesting to note that within
each cluster the serpins belong to the same clade and one explanation for this
phenomenon is that many serpins are a result of gene duplication.
Serpins are involved in many important, highly regulated physiological
processes including blood coagulation, fibrinolysis, apoptosis, hypertension,
hormone transport and inflammation.9, 10, 11 In humans 34 serpins have been
identified to date and most of them have been well studied and characterized
(See Table 1). al-Proteinase inhibitor also called antitrypsin, is quite abundant in
our body at normal physiological levels of about 1-2 mg/mL and increases during
inf~ammation.~
Its main function is to inhibit elastase, which is secreted by
human neutrophils during periods of inflammation. Antitrypsin plays an important
role in human physiology due to its involvement in multiple disease states and
deficiencies. Notably, scientists have been able to link the deficiency of alantitrypsin to emphysema. Emphysema occurs as a result of the inability to
control inflammation, and this situation is further exacerbated by smoking, which
leads to oxidation of the PI methionine to sulfoxide, making the al-antitrypsin
molecule nearly 2000 times less reactive than the thioether.12

Native Structure

The native, or active conformations of serpins have 3 P-sheets along with
9 a-helices, which corresponds to residues 21-389 of al-antitrypsin (Figure 3).

The three P-sheets contain fourteen strands in all, with

P sheet A composed of 5

strands and is the largest as it extends from one end of the serpin skeleton to the
other. P-sheet B contains six strands and P-sheet C has three strands. A unique
property of the third and fifth strands of P-sheet A is that they are parallel strands,
whereas the rest of the strands in p sheets are antiparalleL7 The native structure
also is composed of a reactive center loop (RCL) which is exposed and links P
sheet C to

p sheet A. The RCL contains anywhere from 22 to 27 amino acid

residues labeled P9' to P17, where the PI'-PI bond denotes the scissile bond.
The residues of the RCL define the specificity of serpins, as this area interacts
with the potential substrate binding sites of the target protease. The N-terminal
(PI-PI 7) of the RCL must be at least 17 residues long to permit full insertion of
residues during formation of cleaved and latent forms.

Cleaved Structure

The first structure that was crystallized was of cleaved al-antitrypsin by
Huber et al in 1984.13 The researchers were actually attempting to crystallize the
complexed form of antitrypsin with elastase, but in the process the antitrypsin
molecule was cleaved by elastase and the resulting structure was that of cleaved
antitrypsin (Figure 2). This cleaved antitrypsin showed strand insertion of the
RCL of the antitrypsin into P sheet A between strands 3 and 5. Due to this
insertion the ends of what was the scissile bond at PI were moved about 70 A
apart. This change affects the rest of the serpin molecule, mostly by rearranging

of underlying helices.14 The process of conversion is quite favorable, resulting in
a structure that is stable to denaturation up to about 120°C for the cleaved
variant, while studies show that native serpin is stable to about 60°C.
Calorimetric measurements for heat released on insertion of the RCL in p-sheet

A, and AH has a large value of about 60 kcal/mol.15

Latent Structure

The latent form of a,-antitrypsin was deduced by Tucker et al. in 1995
simply by placing active native al-antitrypsin in a solu.tion of citrate at elevated
temperatures for about 12 hours.16 This variant displayed some similarities to the
cleaved form in that the RCL had been inserted in p sheet A as displayed
through crystal structures (Figures 1 and 3), although residues of the RCL were
still intact in the case of the latent form (Figure 4). These residues provide the
return loop towards the top of the molecule in the latent form, while in the cleaved
form the C-terminal detached residues make up strand 1 of P sheet C.
Formation of the latent structure is favorable for many serpins including alantitrypsin due to its lower energy conformation. This is partially a result of p
sheet insertion, although this variant has been shown to be less stable than the
cleaved form, and scientists suggest that this is due to the loss in stability by
removing a strand from p sheet C.

Figure 1: Cleaved ~ n t i c h ~ r n o t r ~ p s i n ~ '

Figure 2: Native Antitrypsin18

-

Figure 3: Latent PAI-1''

Figure 4: Antitrypsin-Trypsin

r**C)

Serpin-Protease Complex
Complex formation of serpins had proven elusive to researchers and in
1995, Wright suggested that the RCL of serpins inserts into P sheet A, while s,till
preserving the covalent bond to the protease, which results in a serpin:protease
complex with protease at the distal end from the previously uncleaved reactive
site loop.22 This suggested a complex structure similar to the cleaved structure,
except that the protease remains tightly bound in an irreversible complex. In
2000, Huntington had solved the mystery of the complex structure, and the
resulting structure gives insight to how and why the irreversible complex is
formed (Figure 5).' The reaction between serpins and proteases results in a
33% loss in the overall structure for the protease molecule, destabilizing it, while
complex formation actually stabilizes the serpin, although a recent study
questions this claim. The catalytic triad of the protease in this case is altered
such that the serine 195 in trypsin is bound to Met358 of a,-antitrypsin, causing
the active site area to change conformation, making the catalytic triad less
effective in hydrolyzing the acyl bound protease. This conformational change
does not disrupt the hydrogen bond between His57 and Aspl02, but it does raise
the pKa of His57 by about one pH unit.g This conformational trap prevents
catalytic deacylation of the protease, effectively creating a suicide inhibition. This
was quite an important discovery because it established a relationship between
the conformational change in serpins and reaction with proteinase. Also,
reaction with the proteinase causes a dramatic and unique change, one in which

the internal skeleton of the serpin is altered and the proteinase is translocated to
the opposite pole of the serpin molecule as evidenced by the cleaved strand
n . ~ ~
it has also been reported that along
located at bottom of ~ e r ~ i Furthermore,
with changes in conformation of protease, the hydrolysis of the acyl-enzyme
bond is also partially dependent upon the length of the RCL of the serpin.

Kinetic Mechanism of Serpin Protease Reaction

The serpin:proteinase reaction occurs in several steps to form either the
irreversible inhibitor complex or the cleaved serpin and active enzyme. The 5
steps for serpin reaction as a substrate are: 1) formation of the intitial
noncovalent Michaelis complex; 2) active site serine of protease reacting with the
P I peptide of the serpin forming a tetrahedral intermediate; 3) the peptide bond
cleaved resulting in a covalent acyl ester intermediate; 4) formation of the second
tetrahedral intermediate through addition of water; 5) substrate leaves the active
site area. Formation of cleaved serpin occurs as a result of serpins following
steps 1 to 5 through completion of reaction, while formation of the irreversible
serpin:protease complex follows steps 1 through 3 which may be seen kinetically
in Figure 7 and chemically in Figure 8.

Figure 7: Kinetic Mechanism of ~ e r p i n s ~ ~
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The first pathway describes the formation of the cleaved substrate serpin
and has an overall rate constant of k3. The second pathway describes the acyl
intermediate becoming blocked by ineffectiveness of proteinase to complete the
proteolysis reaction, and this occurs before step 4. As a result of the loop
insertion induced conformational change within the serpin and the resulting
distortion of the proteinase active site. The overall rate constant for
serpin:protease complex formation is described by kq. Once inactivation of
proteinase as a result of complete loop insertion of the RCL has occurred, this
results in the proteinase being unable to undergo deacylation. As a result, the
serpin is bound irreversibly to the proteinase following the substrate suicide
kinetic pathway, kq.
The effectiveness of this reaction is displayed by measuring the k5value of
the complex conversion to cleaved serpin. The k5 value represents deacylation
of the serpin:proteinase and studies show that k5 is at least 5-7 orders of
magnitude less than k3. The relative proportion of the acyl enzyme complex
which is converted to either cleaved serpin or irreversible suicide complex
depends on the relationship between k3 and kq. If k3 >> kq, the major end product
is free enzyme and cleaved serpin, while kq >> k3 gives an irreversible serpin:
proteinase complex as major end product. The SI is given by SI = (k3 + kq)/kq,
and where kq is much greater than kgthen the SI is -1. The key to forming the
complex is to have loop insertion occur before the bond is hydrolyzed. Different
factors lead to the variation in this ratio which favors one form over another.

Serpin-Ligand Interactions

Determinin~the Interaction
The ability of serpins to bind to a variety of ligands is useful in studying
ways to alter serpin activity. Since serpins play vital roles in our biological
systems, studying serpin ligand interactions becomes an invaluable tool in
helping to discover serpins' role in the body, and how altering their activity affects
a biological system. The binding of serpins to proteinases in order to inhibit them
is the most common serpin interaction studied, and in many cases this interaction
may be influenced by a cofactor such as heparin. Serpins in this group include
antithrombin, heparin cofactor II, protein C inhibitor, plasminogen-activator
inhibitor-I (PAI-I), protease nexin-I, and kallistatin. Protein ligands bound to
serpins may also have an effect on activity and such is the case with PAI-1
~ ~ serpins depend on ligands in order to carry out
binding to v i t r ~ n e c t i n .some
their function, such as the transport of thyroxine by thyroxine binding globulin
(TBG) or the inhibition of blood vessel growth by pigment epithelium derived
factor (PEDF).
There are many different techniques to identify and analyze ligand-serpin
interactions such as yeast 2-hybrid analysis, spectroscopic techniques, kinetic
methods, surface plasmon resonance, and affinity chromatography. The
mapping of binding sites on serpins has been studied using chemical
modification, site directed mutagenesis, epitope mapping, and crystallography
methods.27 No one method is universally better than the other and many serpin-

ligand interactions have been discovered by multiple techniques to verify the
results.
Genetic mapping has allowed us to determine the structure of serpin
molecules and their target proteinases. In this case, A simple method to verify
whether a ligand may inhibit a serpin is to simply incubate the serpin with ligand,
and to measure for activity of the serpin. If serpin activity has been affected, then
it is presumed that ligand is interacting with it. Determining a potential ligand
may be done using many methods. For those serpin molecules which have been
known to bind to non-proteinase ligands for biological reasons, designing and
synthesizing novel ligands may be aided by ligand structure. Currently, there is
much work being done to improve upon heparin activity creating analogues of its
pentasaccharide substructure.
Gel filtration chromatography has proven useful in discovering natural
ligands of a serpin. There are many different types of columns, such as sizeexclusion, and ion-pair, and different techniques used such as thin layer, and
affinity chromatography. This method requires the passage of a biological fluid
such as blood plasma thru a column, to which the natural serpin is bound. This
elution time is compared with that of free serpin through the column, known as
resolution. If there is difference in elution time, it suggests that the serpin is
complexed. This is the method which led to the known association between PAI-

1 with ~ i t r o n e c t i n . ~ ~

Once a potential ligand has been identified, confirmation of interaction
must be determined. Solid phase binding methods may be useful for this
purpose. Here, once a potential ligand is identified, it is then immobilized onto a
matrix, which is then packed onto a column. A solution containing the target
serpin is then eluted through the column. This particular method has been used
to establish the binding of several serpins to glycosaminoglycans such as
heparin. Examples include antithrombin, heparin cofactor II, protease nexin-I,
protein C inhibitor, PAI-I , and kal~istatin.~. The next step would be to measure
the affinity of the ligand-serpin interaction. There are several techniques which
have proved useful in determining this affinity. One popular technique is solidphase binding methods. One of the species is immobilized on a solid support,
while the other species is added in solution. Once equilibrium is reached, the
solid phase is separated from the solution phase and washed. The amount of
species bound to the immobilized species may then be quantified. This method
has been proven useful for verifying high affinity interactions of a ligand with a
serpin, such as protease nexin 1 and C1-inhibitor with collagen.29"1

This method

is simple, but the major disadvantage is that the immobilized species may be
heterogeneous with respect to attachment to the surface. In order to overcome
this obstacle, competitive binding approaches may be used. Here the approach
is similar to the previous method except that one species is bound to a known
ligand, and this complex is progressively dissociated by adding increasing
concentrations of the partner species. The difference in total serpin

concentration required to achieve equivalent saturation of the immobilized ligand
in the absence and presence of the competitor ligand provides an accurate
measure of concentration of the solution serpin-ligand complex independent of
the nature of immobilized serpin-ligand interaction.

Quantitatinq the Interaction
For those situations where one may not be able to immobilize a species
onto solid phase, other techniques exist to quantitatively measure the serpinligand interactions. One such technique is the use of intrinsic or extrinsic
spectroscopic probes to study the interaction. Intrinsic probes are usually found
within the aromatic residues of the serpin, which have characteristic near UV
absorbance and fluorescence properties, which may be altered as a result of
ligand binding. Tryptophan fluorescence has been particularly useful for intrinsic
fluorescence measurements. Antithrombin high affinity interactions in the
concentration range of 10-20 nM have been studied using fluorescence. It also
has proved useful in detecting other serpin-ligand interactions as well. For
example, kallistatin, a serpin expressed in endothelial and smooth muscle cells of
blood vessels, undergoes a 50% enhancement in intrinsic fluorescence upon
binding to heparin.32 Where the protein ligand possesses intrinsic fluorescence,
a difference between the fluorescence of an equimolar mixture of serpin and
ligand and the summed fluorescence of free protein and ligand may help indicate

whether the serpin-ligand interaction perturbs the intrinsic fluorescence of one of
the interacting components.33
In many cases, the fluorescence energy of the serpin is not affected by the
binding of a ligand, and hence an extrinsic fluorophore may be used. These
extrinsic fluorophores bind noncovalently to the serpin, which changes the
fluorescent characteristics of the fluorophore. Examples of the use of
noncovalent fluorescent probes to study serpin-ligand interactions include TNS,
ANS, and bis-ANS. ANS has been studied in the particular case of binding to the
hormone pocket of the serpin, TBG, with nearly a four fold increase in its
fluorescence emission.34935 Here, binding of hormone displaces the fluorophore
and this in turn causes a decrease in fluorescence, a useful technique for
quantifying the affinity of the hormone for the serpin. When conducting binding
studies with a fluorophore probe, it is important to assess whether the labeling
has affected the interaction. This can be done by competitive binding studies in
which the unlabeled serpin or ligand is used to compete with the labeled
component for binding the species. This was done with the binding of S195A
tPA or anhydrotrypsin to recombinant PAI-1 labeled at the P I ' reactive center
loop residue with the fluorophore, NBD, through an engineered P I ' ~ ~ s t e i n e . ~ ~
Binding of the labeled PAI-1 to inactive proteases was shown to be weaker then
was the unlabeled wild-type PAI-1, by studying the fluorescence changes linked
to the displacement of the labeled PAI-1 from its complex with proteinases by
. ~ ~ TNS, and bis-ANS have played an important role in
unlabeled ~ e r p i n ANS,

determining structural changes in the serpin as a result of binding to the ligand,
where a ligand bound to serpin causes a change in serpin structure, and this
translates into a change in fluorescence. Fluorophores may be used to measure
potential binding sites on serpin molecules, because of their small structure,
propensity to bind to hydrophobic pockets and the change in fluorescence which
may be easily detected. As of the present time, binding studies with these small
organic ligands have only been carried out on structural variations of PAI-1.27
This interaction may be further studied through the variability in structure and
function in serpins to perhaps elucidate potential ligands, which is the focus of
this dissertation.

Figure 9: Organic Fluorophores-ANS, TNS, bis-ANS

2'6-Anilinonapthalenesulfonic Acid (ANS) 6-(p-Toluidino)-2-napthalenesulfonic acid (TNS)

I
OH
4,4'-Dianilino-I , I '-binapthyl-5'5'-disulfonic acid (bis-ANS)

Table 2: Selected serpins and their known proteinase and nonproteinase ligands3'

Serpin

Nonproteinase ligands

Proteinase
target

Antithrombin
Xa,
Antichymotrypsin
al-Proteinaseinhibitor

Heparin, heparan sulfate

C1-inhibitor
CBG
Headpin

Heparin, collagen
Corticosteroids

Thrombin, factor
factor IXa
Cathepsin G
Neutrophil
elastase
Cls

-

Heparin cofactor factor I1
Hsp47
Kallistatin
Maspin
MENT

Heparin, derrnatan sulfate
Collagen
Heparin
Collagen
DNA

PEDF
PI10

DNA, AP 1 4 2 peptide
-

-

Lysosomal
cathepsin (?)
Thrombin
-

Tissue kallikrein
-

Nuclear cysteine
proteinase (?)

Activin
Heparin, heparan sulfate, vitronectin
thrombin, aPC
Heparin, collagen

-

-

Nuclear
proteinase (?)
aPC, thrombin,
acrosin, uPA
Thrombin, uPA

Protein C Inhibitor

Heparin, retinoic acid

Protease nexin-1
TBG
ZPI

Heparin, collagen
Thyroxine, triiodo thyronine
Protein Z

tPA, uPA,
-

-

Factor Xa

Figure 10: Heparin pentasaccharide bound to antithrombin dimer40

The interaction between serpins and ligands from a mechanistic point of
view gives a better look at the potential effect of ligand binding. Because serpins
go through a branched pathway suicide substrate mechanism, which permits
formation of either the cleaved non-complexed or cleaved complexed form, the
effect of the ligand on serpin function may be determined. This can be done by
titrating a fixed concentration of enzyme with increasing concentrations of serpin
in the presence and absence of ligand. After this reaction has reached

completion, the residual enzyme activity is determined by monitoring the initial
rate of hydrolysis utilizing a suitable chromogenic substrate.4 0 ~ 4 1 -rhe
stoichiometry can then be determined from the x-intercept of a plot of residual
activity vs. the ratio of serpinlprotease concentration. If the ligand has affected
the serpin pathway, then either or both rate constants of mechanistic pathways
will be altered. This pattern was seen for heparin reaction in the presence of
antithrombin, thrombin and factor Xa.42v43 Measurements of the change in Kobs
can help to provide a means of measuring the affinity of serpin-ligand interaction.
Measuring change in kbs
for serpin:protease as a function of ligand
concentration should be nearly equivalent to a binding curve for serpin-ligand
interaction. This has been seen extensively with antithrombin-binding heparin
pentasaccharide on the kinetics of antithrombin reaction with its target
proteinases.
More complex kinetic perturbations may also be studied. One common
observation is that the ligand produces a bell shaped dependence of Kobson
ligand concentration in which the rate constant increases then plateaus at a
peak, and then decreases. This effect is usually seen in the case of heparin,
where the ligand binds both the serpin and proteinase.44345 The initial increase is
the result of forma,tion of protein-ligand binary complex and when the ternary
complex reacts with proteinase. The decrease at higher ligand concentrations
reflects progressive blocking of ternary complex formation due to excess free
ligand competing with the serpin-ligand complex for proteinase.

In order to measure the specificity of the ligand serpin interaction,
substitution of important residues on the serpin which interact with ligand or
changing ligand structure may be done. In the case of glycosaminoglycans, the
specificity was determined by immobilizing serpin on a gel while passing different
structural variants of ligand through the gel. This procedure was done for lowaffinity and high-affinity binding heparin. Here, the high-affinity heparin had a
specific sequence giving it the high affinity binding.46-50 Mutagenesis is also a
powerful tool for determining potential binding site on a serpin. In this approach,
an expression system and a screening assay are required to identify any mutants
with defective ligand binding but which are normally folded. Once the region has
been identified, specific residues important in binding may be determined by
mutagenesis and analysis of interaction. An exosite on antithrombin in the RCL
region was shown to be quite important in factor Xa binding.51.52 This procedure
has helped to establish common binding sites on antithrombin, heparin cofactor
II, PAI-I , and protease nexin-I in interaction with glyco~aminoglycans.~~
The most preferred method of mapping a ligand binding site on a serpin
molecule and establishing whether a ligand has the capacity to induce
conformational changes on the serpin is to solve the crystal structure of the
serpin in the free, or unreacted state and complexed to ligand by X-ray
diffraction. Here, ligand induced changes in antithrombin caused by heparin of
both the binding site and the reactive center loop were easily evident by the free
and complexed structures. In the case of protein C inhibitor in complex with two

known ligands, retinoic acid and heparin, the structure of the complex has yet to
be determined, although the free structure suggests binding sites of the hormone
and heparin. The structure of the ternary bridging complex of heparin with the
serpin and two proteinases, thrombin, and activated protein C, show that the
serpin and proteinase would have to bind to opposite sides of a common site on
heparin for the serpin RCL to interact with proteinase active site.54

Heparin Pentasaccharide-Antithrombin
Among the many ligands studied to date, several successfully inhibit
serpins, and they are listed in the following table. Of particular interest is
heparin, due to its wide range of targets within the serpin family, and which is a
prime example of how ligand serpin interactions can yield therapeutic results.
Heparin is a naturally occurring heterogeneous sugar polysaccharide found in the
human body, and it plays a vital role in anticoagu~ation.~
The polymer form is
comprised of 5 different monosaccharide units in varying amounts and is very
acidic due to sulfate and carboxylic acid groups. Heparin pentasaccharide,
which is the form of heparin used to bind to serpins, contains five unique sugar
units denoted by DEFGH and has a molecular weight of about 1500 glmol.
Heparin activity with antithrombin has proven to be especially important for
therapeutic reasons. There are two distinct mechanisms for heparin-activated
antithrombin inhibition of factor Xa and thrombin. The interaction of high-affinity
heparin, or pentasaccharide H5, expels the partially inserted RCL residues

altering the conformation of the P I - P I 0 reactive center and exposing an exosite
in antithrombin (Fig. 5).55-59This sequence of events is called the conformational
activation of antithrombin. The altered RCL in heparin-antithrombin co-complex
is easier recognized by factor Xa and this results in accelerated cleavage of the
P I - P I 0 bond and quick formation of the covalent inhibited complex (E*-AT* in
Fig. 2). As a result of activation of antithrombin, factor Xa inhibition is increased
sufficiently. Thrombin inhibition, in contrast, is accelerated only twofold through
the conformational activation mechanism (see Fig. 4).51 The main effect of
heparin in accelerating thrombin inhibition is due to a bridging mechanism. Tight
binding of antithrombin to the H5 sequence in full length heparin is followed by
the binding of thrombin to the same chain at non-specific sites to form an
antithrombin-heparin-thrombin ternary complex (Fig. 5). Thrombin then diffuses
along the polyanionic chain to encounter the inhibitor resulting in a -2,000-fold
acceleration in inhibition under physiological conditions. A saccharide length of
about 18 residues is needed to concurrently bind thrombin and antithrombin for
Thus, while sequence-specific H5 is necessary for
the accelerated inhibition.60761
tight binding of heparin chains, the H5 alone cannot potentiate antithrombin
inhibition of thrombin. Here again the ligand in this case was reacted in the
presence of both antithrombin and thrombin where heparin concentration was
varied and a bell-shaped dependence of acceleration on the concentration of
heparin chains, characteristic of a bridging mechanism, was observed.

Figure 11: Heparin Pentasaccharide
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Another serpin-ligand interaction of interest is that of plasminogen
activator inhibitor-I (PAI-1) and vitronectin. PAI-1 is a member of a group of
proteins known to inhibit plasminogen activators. When fibrinolysis occurs,
tissue plasminogen activator (tPa) converts protein plasminogen into plasmin.
As a result, plasmin then degrades fibrin along with providing for localized
protease activity including ovulation, and cell differentiation. PAI-1 is the main
inhibitor of tPA, and controls the production of plasmin, and as a result controls
f i b r i n o ~ ~ s i Vitronectin
s.~~
is a large glycoprotein with a molecular weight of about
75 kDa, and it also plays an important physiological role. It has been known to
target antithrombin-thrombin complex, along with glycosaminoglycans including
heparin playing a role in ~ o a ~ u l a t i o nIt's
. ~ major
~ - ~ ~role is debatable but it is
present in tissues and helps to promote cell adhesion. Interaction of vitronectin
with PAI-1 is not known to inhibit the activity of active PAI-1, as vitronectin bound

to PAI-1 is bound to the lower half of the serpin, in particular binding to residues
on helix F, and strands 3 and 5 of P sheet A.

Thyroxine-TBG; Corticosteroid-CBG
Globulins including both thyroxine binding globulin (TBG), and
corticosteroid binding globulin (CBG) bind to smaller organic molecules, and give
us more insight into small molecule influence on serpin activity. Globulins play a
major role in the immune system as they are carriers of antibodies. Thyroxine is
a derivative of the amino acid tyrosine, and contains 4 iodine atoms. It is also the
major hormone secreted by the thyroid gland. Nearly all of the thyroxine in the
body is bound to TBG. TBG's most vital role in the body is as a carrier of
thyroxine throughout the body so that it may help regulate metabolism and
physical development. The structure of TBG and the binding site of thyroxine is
still unknown to this date. Corticosteroids are a family of compounds including
cortisol which is an adrenal hormone. There have been nearly a hundred
synthetic derivatives of cortisol, which are being sold as drugs. Their main role is
to block allergen and inflammatory activity by blocking prostoglandins, yielding
powerful anti-inflammatory activity. The structure of CBG has been solved,
although as is the case with TBG, the binding site of corticosteroids is unknown.

Retinoic Acid-Protein C Inhibitor
Retinoic acid interaction with Protein C inhibitor is also of interest, due to
similarities in size of retinoic acid and the fluorophore ANS. Protein C inhibitor's
physiological role is to inhibit activated protein C and thrombin through it's
interaction with heparin, playing a dual, competing role in the anticoagulation
pathway.54762 Heparin is believed to bind to protein C inhibitor at the H helix,
which is at the backside of the molecule directly behind P sheet B. Retinoic acid
is a organic derivative of vitamin A found in the epidermal and dermal layers of
the skin, whose function it is to aid in the development and maintenance of bones
and skin. The consequence of an interaction of retinoic acid with protein C
inhibitor is unknown although it is thought to be a delivery protein in the same
way that TBG delivers thyroxine throughout the body.62 Retinoic acid is
hypothesized to bind in an area near helix A of protein C inhibitor, although the
three dimensional structure of protein C inhibitor is not yet known.
In 2001, a group of researchers documented an association between bisANS and PAI-1.67 The structures of the conformations of PAI-1 show great
variability between the active and the cleavedllatent forms. In the native
structure, there is a large hydrophobic pocket located adjacent to strand 1 of P
sheet A, and between both helix D and A, which is missing in the variants due to
strand insertion. When the conformational variants were tested for fluorescent
activity in the presence of bis-ANS, the native conformation displayed an
intensity much greater than for cleaved, latent, or PAI-1 complexed to urokinase

type plasminogen activator (uPA) as can be seen from graph 1.67 Since the
hydrophobic region is unique to the native form, and this area consists of mainly
hydrophobic residues, it is hypothesized that bis-ANS binds in this particular
region, which can be seen on Figure

The residues implicated in binding to

bis-ANS are shown in red, while those residues involved in vitronectin binding
are shown in green.

Figure 12: Fluorescence of 4 mM bis-ANS with selective conformations of PAI-1
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Figure 13: Binding site of bis-ANS and vitronectin on PAI-1.
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Chapter 2: Methods
Proteins and Stock Solutions

Bovine al-antitrypsin (MW 57kDa) purchased from Sigma was in
lyophilized powder form. 5 mg of antitrypsin was dissolved in 965 pL of 20 mM
Tris-HCI buffer, pH 7.5, containing 100 mM NaCl (TBS) to give a stock solution of
0.1 mM. Smaller volumes were aliquoted into 1.5 mL tubes at a concentration of
10 pM and kept at 4°C for storage. Bovine trypsin (MW 25 kDa) was also
purchased from Sigma. Twenty mg. of the trypsin stock was diluted with ImM
HCI buffer to give a concentration of 43.5 pM in solution and was stored at -20°C.
Human al-antichymotrypsin (ACT) was purchased in powder form from
Calbiochem, while bovine a-chymotrypsin (CHY) was purchased from Sigma.
One mg ACT was dissolved in 615 pL TBS, to give a stock concentration of 25
pM, while 10 mg CHY was dissolved in 10 mL 1 mM HCI solution to give a stock
concentration of 40 pM, which was subsequently diluted to desired
concentrations for creating ACT-CHY complex.
The substrate used for the CHY assay was Suc-AAPF-pNA (MW=625
glmol), which was bought from Sigma in lyophilized powder form."

Substrate is

initially dissolved in 1 ml DMSO to 3 mM, which was diluted to 2 mM with

additional TBS. On reaction with CHY the para-nitroaniline group is cleaved from
peptide and displays a yellow color. This is measured by UVNis at 405 nm.
The substrate used in the trypsin assay was Nu-benzoyl-L-arginine pnitroanilide (L-BAPNA), which was purchased from Sigma in lyophilized powder
form.69 L-BAPNA has a molecular weight of 435 Da. L-BAPNA substrate was
dissolved in 20 mM Tris-HCI buffer, pH 7.5, containing 100 mM NaCl to give a 1
mM stock solution. The 1 mM L-BAPNA was placed at 4°C fridge for storage.

Km and Vmax of CHY and TRY

The Km and Vmax determinations for Suc-AAPF-pNa reaction with CHY
was carried out by reacting 10 nM CHY with various concentrations of substrate
ranging from 0 to 100 pM in 1 mL TBS solution. The slopes of the reaction were
recorded and the slope value were plotted against substrate concentrations. A
curve fit based on the equation, y = (Vmax* x)l(Kd + x), was fit to the data points
on the graph.
The Km determination for the substrate was determined by aliquoting 10
pL of the 43.5 pM stock solution into 900 pL TBS. 200 nM trypsin was titrated
with L-BAPNA ranging from 0 to 500 p ~ . The
~ ' Km was determined by fitting the
data to the previous equation.

The stoichiometry o f inhibition (SI)
10 nM CHY was incubated with a range of concentrations of ACT from 0
to 40 nM in 100 pL TBS overnight at 25°C. Next, the solution was diluted with
850 pL of Tris-HCI buffer and 50 pM Suc-AAPF-pNA substrate was added to give
a total volume of 1 mL. The absorbance was recorded for 3 min. at 405 nm. The
values of the slope measurements were noted and a plot of slope versus
[ACTIo/[CHYlowas prepared. From the plot, a linear regression of the data to
obtain the point at which the line crosses the x axis gave the stoichiometry of
inhibition. The reaction of trypsin with antitrypsin is monitored with L-BAPNA
substrate. 200 nM trypsin is reacted with 0 to 500 nM antitrypsin in 1 ml TBS
with 250 pM L-BAPNA.

Preparation of cleaved serpin
ACT
Cleaved ACT was prepared by diluting stock ACT solution into 1 ml TBS
to a concentration of Ip ~ . Human
~ '
neutrophil elastase (HNE), purchased from
Calbiochem, was added to give a final concentration of 20 nM or 1/50ththe
concentration of ACT. With the concentration of HNE being only a fraction of
ACT, complex formation does not occur. The solution was incubated at 37°C for
thirty minutes and every 5 minutes a sample was checked for residual CHY
activity using hydrolysis of 50 pM Suc-AAPF-pNA substrate. The solution was

then stored at -20°C, when the residual activity reached 3%, or 97% cleaved
ACT was formed.

AT
10 pM native antitrypsin solution is diluted to 1 pM in 1 mL TBS. 40 pM
porcine pancreatic elastase (PPE), purchased from Sigma, was added to give a
final concentration of 1 pM. The ratio of serpin to proteinase was 1:I.
This
solution was incubated at room temperature for 30 minutes. Samples were taken
every 10 minutes to check for activity by adding trypsin and 250 pM L-BAPNA
substrate, and after 90 minutes the activity of trypsin was -96%, suggesting 96%
cleaved antitrypsin.

Preparation of latent serpin
ACT
Formation of latent ACT was done by diluting a stock solution of native
ACT to 1 pM in 1 mL TBS and then placed in 37°C warm water bath.72 The
activity of CHY against ACT was repeatedly tested using hydrolysis of 50 pM
Suc-AAPF-pNA substrate. In about 4 week's time, the enzymatic activity
reduces to only about 5% suggesting -95% latent or polymerized form.

AT
The latent form of a,-antitrypsin was prepared as previously reported.73
The 10 pM stock solution of antitrypsin was diluted 10 fold with TBS to yield a
final concentration of 1 pM antitrypsin. The solution was incubated at 67°C for

approximately 24 hrs. Samples were taken periodically to check for activity by
adding trypsin and 250 pM L-BAPNA substrate, and after 24 hrs, antitrypsin
activity was about 3%, suggesting 97% latent or polymerized form. Antitrypsin
forms the latent complex at higher temperatures, but it is between 65-68"C, that
formation of latent AT is maximized and polymerization is minimized.73 After 24
hours, the latent AT solution was stored at -20°C until further analysis.

Preparation of Serpin-Protease Complex

Native ACT and CHY, each at a concentration of 1 pM, were mixed in a 1
mL solution of TBS. The mixture was incubated for thirty minutes. Using the
CHY assay previously discussed, the residual CHY activity was repeatedly
measured. Following completion of reaction, the residual CHY activity is
expected to be near zero. After verification that complex formation is complete,
sample is stored at -20°C.
Formation of AT-TRY complex was very similar to ACT-CHY complex.
Equimolar ratios of native AT and TRY were mixed at 1 pM in 1 mL TBS. The
mixture was incubated for 30 minutes, and assayed for activity using the TRY
assay previously described. Residual TRY activity is expected to be near zero.
After verification that complex formation was complete, sample was stored at 20°C.

Preparation of stock solutions of fluorophores

For this study, three hydrophobic aromatic fluorescent dyes have been
chosen 2-anilinonaphthalene-6-sulfonic acid (2,6-ANS), 2-(p-toluidinyl)
naphthalene-6- sulfonic acid (TNS), and (4,4'-dianilino-I ,I1-binaphthyl-5,5'disulfonic acid (bis-ANS). ANS was purchased from Sigma as a lyophilized
powder (>97% purity, HPLC). TNS was also purchases from Sigma in
lyophilized powder form (>97% purity, HPLC), while bis-ANS was purchased
from Molecular Probes in lyophilized form also (>95% purity, HPLC). 260 mg
ANS was dissolved in 1 mL DMSO then diluted with 1.4 mL TBS to give a 34 mM
stock solution. This solution was further diluted to give final concentration of 3.4
mM. Twenty mg. of TNS was dissolved in 75/25 ethanol (mL)/DMSO (mL)
mixture to 1 mL to give a 6.8 mM solution. Once fully dissolved, it was further
diluted with 30 mL of TBS to give a 1.7 mM stock solution. The bis-ANS was
previously diluted in 2 mL deionized water. The absorbance of the solution was
detected and measured at 395 nm, and using Beer's Law, the concentration was
measured to be about 2.4 mM, with extinction coefficient of 23,000 cm-' at 395
nm.74 This solution was further diluted to 1.25 mM with 1.84 mL TBS.

Determination of emission wavelength of fluorophores

In a 3 mL acrylic cuvette, 25 pL of 3.4 mM ANS was pipetted into a 1 mL
solution of TBS to give a 85 nM solution. The slits for the emission and excitation

monochromators were .5 mm. The excitation wavelength was set at 404 nm,
and emission was recorded from 425 to 600 nm. TNS spectrum analysis was
performed in a manner similar to ANS. For TNS, the excitation wavelength was
330 nm, while emission was recorded from 350 to 600 nm. The saturation
concentration of TNS is about 20 pM. For bis-ANS the excitation wavelength
was 425 nm, while emission is recorded from 440 to 600 nm. The maximum
fluorescence was recorded for each fluorophore and used as emission
wavelengths for titration procedures.

Titration Procedures
Three control samples were titrated: I ) fluorophore in buffer solution, 2)
protease (chymotrypsinltrypsin) and fluorophore in buffer solution, and 3) porcine
pancreatic elastase (PPE) and fluorophore in buffer solution. Using a PEG
coated methacrylate cuvette, stock fluorophore 1 pL at a time up to 50 p M was
added to 1. I mL TBS, to measure the background fluorescence for all following
titrations. The protease plus fluorophore titration was done to ensure no change
in fluorescence occurs due to protease only. PPE and fluorophore control was
measured due to the high concentration in solution during titration. For both
protease and PPE 6.8 mL of 40 p M protease was diluted into 1.ImL TBS to 250
nM. Fluorophore was added 1 pL at a time up to 50 pM. The results determined
that protease and PPE had insignificant effect on the fluorescent activity of
fluorophore.

Gel Electrophoresis Analysis

10% acrylamide gels were made with the following procedure: 2.5 mL of
40% acrylamide, and 2.5 mL of pH 8.8 separating gel buffer were added to a 5.0
mL water solution. Solution was degassed and 10 pL TEMED and 50 pL
ammonium persulfate were added to mixture, mixed and added to gel plates.
For stacking layer, 2.5 mL 40% acrylamide, 2.5 mL pH 6.8 stacking gel buffer
were added to 5.0 mL water. Solution was degassed and 10 pL TEMED, and 50
pL of ammonium persulfate were added to mixture, mixed and added to the
separating layer.
For samples, all conformational variants were at a concentration of 5 pM
in 25 pL TBS. Six pL of 6X SDS buffer was added directly to stock, mixed and
then placed in gel. The protein standard was purchased from Bio-Rad and was
diluted 1.31 by adding 1 pL to 24 pL TBS, and 6 pL 6X SDS buffer. Gels were
run until dye passed through gel. Gels were stained in Coomassie staining
solution for two hours, and then destained in 881517% volume mixture of
waterlmethanollacetic acid overnight.

Modeling of Protein Surface

The trypsin-antitrypsin complex protein structure (1EOZ) was retrieved
through PDB and analyzed using Sybyl. Formal charges were added using the
Gasteiger-Huckel method. A surface scan was conducted using the fast
Connolly method, and the hydrophobic potential was then mapped, where red

designated the most lipophillic residue, while blue designated the most
hydrophilic.

Chapter 3
0 bjectives
There were three main objectives of this study:

1) To determine whether the different conformational states of serpins can be
differentiated with hydrophobic dyes using fluorescence spectroscopy.

2) To determine whether a hydrophobic binding pocket exists in selected
conformational forms of serpins.
3) To determine whether the proteinase inhibitory activity of serpins can be
modulated with hydrophobic fluorophores.

The first objective is probably the most important because it attempts to
develop an easy protocol for assessing the state of serpins. Knowing what
form of serpin is in a given sample using fluorescence could be a good
analytical tool compared to enzyme inhibition studies, due to its sensitivity
and simplicity. Objectives 2 and 3 depend directly on the development of the
first objective. The second objective points to a more fundamental principle.
Many proteins have hydrophobic pockets in their complex 3D structure, and
this study will help to determine if the same is true for serpin molecules.
Along with this, the study will help to determine whether there is a specific

hydrophobic pocket within the serpin molecule, which one or more of the
fluorophores may bind to, and whether this pocket is conserved among the
different conformational structures of serpins. While this study is being
undertaken, favorable interactions will also be sought out as an increase in
fluorescence intensity results from more hydrophobic character of interaction.
This interaction will help to determine if a hydrophobic binding pocket exists,
where it is, and if it is conserved among serpin subtypes such as
antichymotrypsin and antitrypsin. Finally, objective 3 attempts to connect the
hydrophobic pocket to serpin activity. Organic fluorophores will be exposed
to native serpin during conversion into the latent form, to determine whether
the fluorophores have any affect on the rate of this conversion, or modulation.
Modulating the activity of serpin is a useful tool, as it might affect the in-vivo
activity of serpins in humans. Many disease states involve the interactions of
serpins with other molecules and with themselves, and manipulating their
activity could possibility have therapeutic potential.

Chapter 4: Results
Background
The initial goal of this work was to find a simple technique to distinguish
the three conformational forms of a serpin and the serpin:proteinase complex.
Serpins exist in a variety of conformations. A structural change within the serpin
n . ~ structural changes
molecule affects the inhibitory activity of the ~ e r ~ i These
might be monitored by using the change in fluorescence of extrinsic fluorophores,
which bind noncovalently to hydrophobic domains on the surface of protein
molecules.73 Changes in the structure of a protein affect either quantum yield or
affinity of these extrinsic fluorophores, which may be monitored. This has been
~ ~ mutant forms of ovalbumin
shown in studies with ANS and o v a ~ b u m i n .Using
that displayed loop insertion properties, ANS was found to bind primarily when
loop insertion occurred.76 The binding of ANS resulted in an increase in
fluorescence of the complex suggesting additional ANS molecules bound on loop
insertion. Those mutants which do not loop insert showed a decrease in
fluorescence signal, suggesting the release of ANS on proteolytic cleavage of the
RCL. A similar study was also conducted by Egelund et al. in which the
fluorescence decreases on proteolytic cleavage of the RCL of PAI-1.66 Structural

and binding studies were also conducted on PAI-1 binding to bis-ANS, a dimer of
ANS. In addition to binding to bis-ANS, the fluorescence binding studies show
binding to three different serpin variants along with urokinase type plasminogen
activator. See Graph 1, Chapter 1.I
Another study proposed the existence of a hydrophobic binding region
within a mutated form of PAI-1, and designed a ligand based on these findings7'
A study conducted in 1998 by Lomas et al. described the formation of a
canonical inhibitory conformation of a mutant of a n t i t ~ y ~ s i nThe
. ~ ' study went
further to reveal a difference in structure between the wild-type and mutant
forms, and in particular a hydrophobic region within the wild-type between strand
2 of

p sheet A and helices D and E. The study suggested that the hydrophobic

binding pocket may be exploited for creating ligands which do not allow the loop
to insert.
The purpose behind the use of al-antichymotrypsin and chymotrypsin as
model system stems from it's importance in Alzheimer's disease, wherein
amyloid beta (Ap) peptide occurs in insoluble plaques along with other
molecules, including a-antichymotrypsin. In-vitro studies show that Ap binds to

ACT.^^

a,-Antitrypsin was also studied due to Lomas's work in detecting a

potential hydrophobic binding pocket in ~ e r ~ i n s Binding
.~'
studies conducted on
the serpinslproteases will help to understand the characteristics of the variants
and help to probe the differences among them. Using the hydrophobic
fluorescent probes ANS, TNS, and bis-ANS binding studies will enable

determination of favorable binding pockets within the structures. Using this
knowledge, analogues of one or more of the fluorescent probes may be
synthesized in order to target one or more of the protein structures. These
analogues may then be used to design a small molecule marker, which may
affect protease inhibitor. Furthermore, future molecular modeling studies will
help to determine where on the protein these fluorescent molecules bind.

Km and Vmax of (CHY-Suc-AAPF-pNA) and (TRY-L-BAPNA) Assays
CHY-Suc-AAPF-pNA Assay
Suc-AAPF-pNa is a blocked polypeptide ester with a phenylalanine side
chain, which is a preferred substrate for chymotrypsin. 1.25 pL of 280 pM CHY
was assayed for activity against different concentrations of Suc-AAPF-pNA
substrate ranging from 0 to 100 pM, in a 1 mL TBS. The slopes were calculated,
and the values shown on the following graph, where the x value is concentration
of substrate and y value is the slope of the reaction curve. The Km value was 46
4 pM, while Vmax was 108

* 5 mAbs/min.

Figure 1. CHY Assay wlsubstrate

10 nM CHY assay with Suc-AAPF-pNA

TRY-L-BAPNA Assay
Trypsin catalyzes hydrolysis of amides and esters of basic amino acids,
such as the p-nitroanilide of benzoyl arginine (BAPNA). In the assay, 250 nM
trypsin is reacted with various concentrations of 1 mM L-BAPNA ranging from 0
to 500 yM in 1 mL TBS. The following graph was plotted, and x/y values are the
same as for the CHY-substrate reaction. The Km values were 233 f 15 yM,
while the Vmax was calculated to be 39 f 1 mAbs/min.

Figure 2: TRY Assay wlsubstrate

250 nM TRY assay with L-BAPNA

L-BAPNA (pM)

Determining Activity of Stock Serpin Solutions (SI)
a,-Antich~motrypsin
ACT activity was checked against CHY solution by taking 9 samples of 2.5
pM ACT varying from 0 to 40 pL (0 to 100 nM) and mixing each with 8 pL 10 pM
CHY, 50 pM Suc-AAPF-pNA and TBS to 1 mL. The change in absorbance is
measured spectrophotometrically and the fractional chymotrypsin activity at each
concentration of ACT is plotted vs. the nominal ratio of ACTICHY. A straight line
regression slope is used to determine the molar ratio of ACT required to inhibit
CHY. The linear decrease in CHY activity as ACT concentration increases is due
to formation of inhibition complex. The stoichiometry of inhibition obtained form
this plot is 1:1.6. The stock solution of ACT is 63% active and in native form.
Figure 3: S I determination for ACT

al-Antitrvpsin (AT)
The AT SI experiments are conducted in a similar manner to ACT as
outlined in the methods section. AT activity against TRY solution was measured
by taking 6 samples of 25 mM AT varying from 0 to 20 mL (0 to 450 nM) and
mixing each with 5 mL 40 mM TRY, 200 mM L-BAPNA and TBS to 1 mL. The
slope of the curves for trypsin catalyzed hydrolysis of L-BAPNA was measured
spectrophotometrically, by measuring absorbance at 405 nm. In reaction with
native AT, TRY was mixed into buffer solution, incubated overnight, diluted to 1
mL, and then reacted with TRY substrate to check for residual activity. The SI for
AT is 2.3:1,consistent with the supposed activity listed by Sigma.
Figure 4: S I determination for AT

Preparation of Serpin:Protease complex
ACT-CHY
Activity of CHY decreased when equimolar concentrations (1 pM) of ACT
and CHY are allowed to react for at least 10 minutes. Here, complex formation
occurs and due to presence of CHY, no additional CHY is added. A sample of
ACT:CHY was checked for inhibitor activity as a function of time, by taking a 10
pL sample at various times and mixing it with 965 pL of TBS, and 50 pM Suc-

AAPF-pNA, and following the increase in absorbance at 405 nm
spectrophotometrically. The activity of CHY should decrease due to formation of
ACT:CHY complex and after about 10 minutes, the activity of CHY leveled off.
Thus, ACT and CHY at 1 pM were incubated for at least 10 minutes to ensure
the formation of ACT-CHY complex in subsequent experiments.
Figure 5: ACT-CHY reaction wlsubstrate

ACT-CHY Assay with Suc-AAPF-pNa substrate

Time (min)

AT-TRY
Initially, 1 pM of TRY solution was mixed with 1 pM active AT in 1 mL TBS
for 15 minutes. A sample of the AT:TRY solution was checked for trypsin activity
every 3 minutes by taking a 25 pL sample of 5pM AT:TRY, mixing it with 200 pM
L-BAPNA and 865 pL of TBS and measuring the absorbance change at 405 nm
spectrophotometrically. Activity against L-BAPNA substrate decreases
exponentially to about 3% after 12 minutes. Thus, AT-TRY at 5 pM was
incubated for at least 12 minutes to ensure formation of AT-TRY complex in
subsequent experiments.

Figure 6: AT-TRY reaction wlsubstrate

AT-TRY assay with TRY substrate (L-BAPNA)
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Preparation of Cleaved Serpin
ACT
One 1M cleaved ACT is prepared as previously described by digestion
with HNE. The concentration of ACT in the preparation was 1 yM, while the
concentration of HNE was 20 nM. Samples of cleaved ACT was checked for
activity against CHY solution, by taking a 10 yL sample and mixing it with 1 yM
CHY, 50 pM Suc-AAPF-pNA and 964 pL of TBS. This mixture was then
monitored at 405 nm for CHY activity spectrophotometrically, and a linear
increase in absorption indicating first order kinetics. Samples were taken every
15 minutes until CHY activity was greater than 95%, indicating almost complete

loss of ACT activity (98% cleaved ACT after 90 minutes).
Figure 7: Cleaved ACT reaction wlsubstrate

Time (min)

AT
The cleaved conformation is formed using 1 pM PPE and incubating at
room temperature with 1 pM AT as discussed in methods. Every 5 minutes a
sample of AT was checked for activity against trypsin by hydrolysis of L-BAPNA,
by taking a 25 pL sample of 5 pM cleaved AT and mixing it with 12.5 yL 10 yM
TRY in 1 mM HCL, 200 pM L-BAPNA and 863 pL of TBS. The linear absorption
change at 405 nm was measured spectrophotometrically. After about 30 minutes
TRY activity was 96%, indicating 96% cleavage of antitrypsin.

Figure 8: Cleaved AT reaction wlsubstrate
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Preparation of Latent Serpin
ACT
Stock solution of 1 pM native ACT was placed in 1 mL TBS at 37°C in a
warm water bath. Over 4 week's time, the solution was checked for activity by
adding 10 nM with 50 pM Suc-AAPF-pNA in 1 mL TBS, and measuring
absorbance at 405 nm using UVIVis. A linear increase was seen in each
measurement, and this indicated that the reaction followed first order kinetics.
After 4 weeks time, the solution showed nearly 95% residual CHY activity,
indicating that only 5% of the ACT remained active.
Figure 9: Latent ACT reaction wlsubstrate

Days

AT
Using the 10 pM stock solution of antitrypsin, 500 pL was pipetted into a
tube containing 1 mL of tris HCI pH 7.5 buffer to a concentration of 5 pM
antitrypsin, which was then placed in hot water bath at 67°C for optimal latent
formation. Periodically 25 pl samples were measured for TRY activity, by mixing
it with 12.5 pL 10 pM TRY in 1 mM HCL, 200 pM L-BAPNA and 863 pL of TBS.
This mixture was then analyzed for activity as described. Each measurement
displayed linear increase in slope at 405 nm, characteristic of first order kinetics.
After a period of 24 hours, the residual TRY activity was 95%, suggesting 95%
latent antitrypsin. Polymer formation may have occurred even though reaction
took place at 67"C, which is optimal for latent formation.
Figure 10: Latent AT reaction wlsubstrate

Time (hrs)

SI results
Cleaved ACT
The SI test was measured to ensure formation of cleaved ACT using
concentration ratios ranging from 0 to 6 : l of cleaved ACT:CHY and extrapolating
a linear slope to the x-axis. In particular, 10 nM of CHY solution is incubated with
concentrations of cleaved ACT ranging from 0 to 60 nM in a 1 mL solution
containing TBS and 50 pM Suc-AAPF-pNA. Hydrolysis was measured
spectrophotometrically, and the CHY activity displayed as a function of the ratio
of (cleaved ACT)/(CHY) concentrations. Even at a 6 : l ratio of cleaved ACT to
CHY, activity is at or near 10O0/0. Using a linear regression line the slope of SI is
positive, and the value of the SI of cleaved ACT: CHY reaction is undefined.
Figure 10: SI Determination of Cleaved ACT

Latent ACT
To determine the latent ACT SI, samples of latent ACT at concentrations
from 0-60 nm were incubated with 10 nM CHY in 1 mL TBS and 50 pM SucAAPF-pNA. The hydrolysis of substrate was measured 405 nm using UVIVis
spectrophotometer, and the %CHY activity was plotted as a function of the ratio
of (latent ACT)/(CHY) concentrations. The graph displays the ratio of latent ACT
to CHY, and the slope decreases slightly giving an SI ratio of 65:l. Even at a
molar ratio of 6:1, the activity of CHY was unaffected by latent ACT. The ACT
has about 1.5% activity, a decrease of 60% from the native SI.
Figure 11: S I determination of Latent ACT

ACT-CHY complex
ACT-CHY complex was tested for its activity using CHY to ensure that all
of the CHY was in complex. Again, the procedure was similar to other
conformational variants of ACT. A 10 nM CHY solution was incubated with
concentrations of ACT-CHY complex ranging from 0 to 60 nM in 1 mL TBS and
CHY substrate, Suc-AAPF-pNA. The solution was then analyzed for hydrolysis
activity at 405 nm using UV/Vis spectrophotometer, and the CHY activity was
displayed as a function of the ratio of (ACT-CHY)/(CHY) concentrations. From
the above graph, at high molar ratios of 6 to 1, the CHY activity is at or near
100°/~. Any free CHY in solution would have displayed increased activity with
increasing ratios. This is not the case as the activity remains near the control
CHY activity.
Figure 11: SI Determination of ACT-CHY complex
SI of ACT-CHY complex
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Cleaved AT
Varying concentrations of cleaved AT ranging from 0 nM to 1.2pM are
mixed with 200 nM native TRY in 1 mL TBS, along with 200 yM L-BAPNA and
the absorbance was measured at 405 nm. The SI of cleaved AT was 60:l.

Figure 13: SI Determination of Cleaved AT

Latent AT
The AT SI experiments are conducted in a similar manner to ACT SI
experiments as outlined in the methods section and the results are strikingly
similar. Varying concentrations of latent AT ranging from 0 nM to 1.2 pM with
200 nM native TRY in 1 mL TBS with 200 pM L-BAPNA were assayed.
Absorbance change at 405 nm showed linear increase. The ratio of
[latentAT]/[TRY] ranged from 0 to 6. At a ratio of 6 to 1, the TRY activity remains
high, near 100%. The SI ratio for latent AT was about 65:1, indicating that 65
moles of latent AT are required to inhibit 1 mole of native TRY.

Figure 12: SI Determination of Latent AT

AT-TRY complex
Varying concentrations of AT-TRY complex ranging from 0 nM to 1.2 pM
are mixed with 200 nM native TRY in 1 mL TBS, along with 200 pM L-BAPNA.
The linear increase in absorbance was measured at 405 nm. The SI for AT-TRY
was 56: 1.

Figure 14: SI Determination of AT-TRY complex

SI of AT-TRY complex
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UV and Fluorescence Spectrum

The fluorescence spectra were measured before and after titrations for
accuracy. It is important to choose a point where the absorbance values are
quite low (at or near 0.1 mAbs1min) to ensure that the inner filter effect is not
affecting titration studies. The following graph displays the emission spectrum.
for ANS from which an excitation wavelength of 425 nm was chosen. The
emission spectrum was recorded from 450 to 600 nm and an emission value of
526 nm, which corresponds to a maxima peak. TNS was excited at 330 nm, and
emission recorded from 365 to 500 nm. Bis-ANS was excited at 395 nm while
emission was recorded from 425 to 500 nm.

Figure 15 and 16: ANS
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Figure 19 & 20. TNS

UV Spectrum of 20 pM TNS in buffer
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Figure 21 & 22. bis-ANS
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SDS-PAGE
SDS allows proteins to be separated according to their molecular weight.
The latent and native forms of serpins should have a very similar molecular
weight, whilelthe cleaved form will be slightly less due to missing strands at the C
terminus after cleavage of the P I - P I ' scissile bond. SDS is a highly negatively
charged molecule, which denatures the protein by coating the surface with
multiple negative charges, and therefore creates a uniform shape for all proteins
that it comes in contact with. Using an 10% acrylamide gel and low molecular
weight protein standards bought from Bio Rad, gel electrophoresis can be done

with known molecular weights. The protein standards include proteins ranging
from 15-95 kDa, covering the desired range of 50-70 kDa. For all conformations
of antichymotrypsin, 25 pI of 5 pM sample is mixed with 5 pl SDS and placed in
gels after heating. The following gel shows all conformations of
antichymotrypsin, along with protein standards.
Figure 23: SDS PAGE Gel of Serpins

The protein standards include albumin at a MW of 66,000 and is the
second from top mark. Using this as a guide, the different conformations of ACT
can be seen right across from it in rows 2-5. Antichymotrypsin has a molecular
weight range from 65 to 68 kDa, so it should appear close to albumin standard,
and does so. Cleaved ACT is lower than either the native or latent forms, due to

loss of 3 kDa in cleavage. Antitrypsin shows up at about the 55 kDa range, and
both latent and native conformations are as predicted. Cleaved antitrypsin
should show up at a slightly lower molecular weight, yet it shows up at the same
level of both the latent and native versions. More importantly, the complexed
versions of both ACT:CHY and AT:TRY fail to show up on any of the geldudies
conducted. Unfortunately, substrate activity is the only measure of determining
the presence of complex.

Titrations

Introduction
ANS, TNS, and bis-ANS are fluorophores that bind to hydrophobic
pockets of proteins. The fluorophores fluoresce, and when bound to proteins the
intensity of fluorescence light emitted changes. Any variation in the fluorescence
arises from a change in the environment of the fluorophore. This change is
generally an increase on association and a decrease on dissociation of the
fluorophore. This change may be interpreted as monitoring the binding.
In this particular study ANS, TNS, and bis-ANS have been used to titrate
all four conformations of ACT and AT. In order to accurately measure any
association that a fluorophore may have with either molecule, a background
study must be conducted every time the machine is used to check for lamp
stability, to subtract from the titrations, and most importantly to simply make sure
the fluorophore is active, stable and working properly. All titrations were

conducted in 1100 pL Tris-HCL pH 7.5, with fluorophore stock solution added in
1 and 2 pL increments while measuring the emission. Fluorescence data is
interpreted simply as the difference of intensity of each titration minus the initial
reading. The data is converted to percentage change in fluorescence data to
make the readings more useful and to standardize between experiments. Over
time, the lamp used to conduct runs weakens so therefore the raw data results
may actually vary by a great deal. The curve fit used is the KAequation as given,

F

=

((JDFma*)10.5)* ( ( [ L I +KD
,
+ [Rl,) - (([Ll,+ KD + [R1J2- pmxTo),

where f is fit to y. Here KD= [R]o[L]o/[RL],where [RIo is the receptor (serpin,
serpin: protease) concentration in this case is 250 nM and [LIo is the ligand
concentration which changes for each titration point.

ANS, TNS, and bis-ANS backgrounds

The fluorophore is added in small increment to 1100 pLTBS. Mixing
homogeneity is important for an accurate measurement. There should be a linear
increase in emission with increasing fluorophore concentration.

Native ACT

Results of native ACT binding experiments with ANS are displayed on the
following graph (Fig. 24). The graph shows that the native ACT fluorescence
intensity increases by about 100% in reaction with ANS with a AFmax value at 95

+ 2%.

KDvalues for the association are 7.5

+ 0.8 pM suggesting that ANS binds

69

with quite high affinity. At a value of about 7.5 pM, the native form binds with
about twice the affinity of the complex and nearly 8 times greater affinity than the
latent form. This value is lower than the latent form and complex while greater
than the cleaved form. The AFmax and KDvalues show that native ACT binds
tighter than latent and cleaved ACT, while the AFmax values are also higher than
for the cleaved and latent form.
Native ACT binding experiments with TNS display greater affinity of the
fluorophore for the native protein as is the pattern with all serpin variants. The KD
values are 12.1

+ 1.0 pM, similar to all other serpin variants in reaction with TNS.

Native ACT has the RCL exposed while both latent and cleaved ACT have loop
inserted into P-sheet A. This difference in structure may explain the differences
in the KDand AFmax.

Cleaved ACT

Cleaved ACT is taken from stock and placed in 1100 pL TBS. Titration
studies are carried out using 1 pL ANS aliquots at a time reaching a maximum
concentration of ANS at 80 pM, while protein concentration is maintained at 250
nM. It is important to note that there is a residue of human neutrophil elastase
within the cleaved ACT sample, but since the sample ratio is 1:I00 of ACT to
HNE, a concentration of 2.5 nM is negligible in the solution of target serpin and
ligand. The results in figure 24 show a small relative increase in the fluorescence
of ANS. The KDvalue for ACT cleaved-ANS complex was found to be 9.1

+ 3.0

pM by fitting the data to the quadratic binding equation. The AFmax values are
8.8 k 0.8%. Cleaved ACT shows very little change from the background in
fluorescence (about 9%).
Binding studies with TNS are conducted in a similar manner (figure 25).
Since TNS is a more sensitive fluorophore than ANS, titrations are conducted 1
pL at a time to a final concentration of 20 pM in a protein solution of 250nM.
Results with TNS are differentiated from ANS by a greater increase in relative
fluorescence. The point of saturation is at a concentration 4 times less than that
of ACT. Although the KDvalues are almost identical to the ANS reaction at 9.1 k
1.5 pM, the AFmax values are more than 10 times greater at 109 k 8%.
Results from the bis-ANS saturation show the same trend as that for ANS
and TNS. Fluorescence intensity measurements show that the cleaved ACT
shows the lowest change of all the serpin variants. The KDvalues for cleaved
ACT were recorded but are quite suspect due to irregularity in the fluorescence
results. There was quite a bit of variation in the three experiments. The KDfrom
averaging the three experiments come out to 31 k .03 pM, which is 3 times
higher than either ANS or TNS. AFmax values were found to be 166 k 1%.

Latent ACT

Structurally the latent form differs from the cleaved by an extra loop which
returns to the top of the serpin. In addition cleaved ACT has an extra strand in P

sheet C. These two structural differences might cause variations in fluorescence
with different fluorophores.
Fluorescence binding experiments with ANS show some interesting
results. The KDvalues for latent ACT are 51.2 & 6.6 pM,which is about 4 times
higher than the other three variants. This leads to some interesting questions
about the structure of the latent form. The uniqueness of its structure must play
some part in the weak binding of ANS. Latent ACT has an extra loop return
which probably affects the ability of ANS to bind to the scaffold of ACT as it does
on the native and cleaved versions. The AFmax is quite high at 328 k 19%, an
increase of over 3 times the initial background study.
Latent ACT displayed the highest relative change in fluorescence with
TNS. In terms of fluorescence TNS would serve as the best option for identifying
the latent ACT form by fluorescence methods. KDvalues are quite high
according to the curve fit equation, which means that although TNS does not
bind with the same affinity to the latent form as the other variants, the AFmax for
latent ACT is higher with TNS than the other fluorophores. The change in
fluorescence is greater than 700%. KDvalues for reaction with TNS are 12.9 &
0.6 pM, which are in line with affinities of other serpin variants of ACT for TNS.
The AFmax values for this reaction are 765 & 15%, a value nearly 2 times greater
than the next highest value. This suggests that the latent form has more
hydrophobic pockets to which TNS associates than other variants.

Bis-ANS shows the second highest change in fluorescence. Its relative
change in fluorescence is nearly 400 times the initial fluorescence reading. The
KDvalues are 10.7 k 4.2 pM, displaying an affinity lower than either the native
form or the complex. The AFmax values are 494 & II%, a 500% increase from
the initial background studies. This value pales in comparison to the complex
reaction with bis-ANS, but it is nearly equivalent to the native from. From these
experiments, it is safe to assume that both TNS and bis-ANS are suitable
fluorophores for detecting the presence of the latent form.

ACT-CHY complex

The results of relative fluorescence intensity change show that the
complex displays the greatest increase of all four structures on binding
fluorophore. The fluorescence intensity change of nearly 33% relative to the two
native active protein structures, and is not due to binding to CHY. ANS titrations
with a-chymotrypsin showed minimal fluorescence binding.
In binding experiments conducted in the presence of ANS fluorophore, the
ACT-CHY complex displayed a KDvalue of 15.4

+_

1.9 pM, a value only slightly

different from the other serpin variants. The AFmax value for this reaction was
286 k 4%, which is on the higher end of the spectrum, although lower than the
latent form.
In reaction with TNS, the results were similar to the native form. The KD
values for complex reaction with TNS are 11.2 & 1.4 pM, while the AFmax values

are 369

+ 22%.

The AFmax values for both the TNS and ANS reaction show that

complex interaction with these fluorophores consistently creates a noticeable
change in the intensity of fluorescence.
Complex binding with bis-ANS gave a KDvalue of 4.5

+ 0.8 pM, lower than

complex reaction with other fluorophores, making bis-ANS the most sensitive
fluorophore in reaction with ACT-CHY complex (figure 26). The AFmax value at
3569

+ 249% shows the greatest increase in intensity.

In fact the AFmax value is

nearly 36 times greater than the background, a noticeable difference in intensity.
Bis-ANS is clearly a good candidate for further study and analysis in its
interaction with the ACT-CHY complex.

Figure 24

ANS titration of ACT- Native, Cleaved, Latent
and ACT:CHY complex
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Figure 25

TNS titration of ACT- Native, Cleaved, Latent
and ACT:CHY complex
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Figure 26

B-ANS titration of ACT- Native, Cleaved, Latent
and ACT:CHY
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Native AT

Native AT shares a structural conformation similar to native ACT in the
fact that it has an exposed RCL. The RCL of native AT differs from native ACT
by four amino acids, and its P I group is methionine as opposed to arginine for
native ACT. As a result of this similarity, binding studies should show a pattern
similar to ACT, as is seen for the cleaved and latent forms.
Binding studies conducted with ANS reveal that the KDvalue is 10.4

+ 0.7

pM and the AFmax value is 185 k 3%. Native antitrypsin shows greater affinity
for ANS than either the latent or complex form. In reaction with both TNS and
bis-ANS, native AT has higher AFmax values than the cleaved form pointing to
greater association of fluorophores to the native form versus the cleaved. KD
values calculated for TNS and bis-ANS are 9.3 k 0.6 pM, and 2.8
AFmax values are 976

+ 0.3 pM, while

+ 26%, and 573 + 17%. Affinity values point to the fact

that bis-ANS is the best fluorophore for binding to the native form, while AFmax
values point to TNS as being the best in determining increase in fluorescence.

Cleaved AT

Cleaved AT is formed by reaction with porcine pancreatic elastase (PPE).
The procedure calls for a equimolar ratio of elastase to serpin thus there is an
appreciable amount of PPE remaining in the reaction thus pancreatic elastase is
also titrated to correct for background.

Results of the cleaved AT binding to ANS is shown on figure 27. Cleaved
AT shows the lowest relative increase in fluorescence intensity as also noted with
cleaved ACT. The KDvalue was found to be 10.3

+ 0.9 pM, while the AFmax

+

value was 153 4%.
Both TNS and bis-ANS binding results for cleaved AT are similar to results
for ANS in that relative fluorescence changes are the lowest of all the
conformations. The KDvalues for TNS bound to cleaved AT are 11.6 2 1.4 pM,

+ 45%. For bis-ANS the results are 1.2 + 0.1 pM for
KD,while the AFmax is 401 + 6%. There is not much difference in affinity

while AFmax values are 743

between ANS and TNS, while bis-ANS at I.2 pM binds at about 10 times less
concentration.

Latent AT

Binding studies to ANS, TNS, and bis-ANS are seen on figures 23-25.
Latent AT shows some similarity to latent ACT in its high KDvalues. According to
the curve fit results, bis-ANS would be the best candidate for binding studies with

+

latent AT. The results for binding to ANS are 17.3 0.8 pM for KD,while the
AFmax values are 247
values of 686
KDand 869

+ 4.

TNS give a KDvalue of 7.9 2 0.5 pM and AFmax

+ 18%. In reaction with bis-ANS, the values are 3.6 2 0.4 pM for

+ 32% for AFmax.

Bis-ANS shows the greatest change in

fluorescence according to the graphs, and the AFmax values are highest for bis-

ANS, while KDvalues suggest that TNS has the greatest affinity for latent AT of
the fluorophores studied.
AT-TRY complex
The AT-TRY complex shows similar results in that AFmax values for the
complex are higher for all three fluorophores bound to it. KDvalues for ANS,
TNS, and bis-ANS are 21.3 5 0.6 yM, 10.5

+ 0.4 pM, 1.6 + 0.1 pM respectively.

Here, it is quite evident that bis-ANS shows the greatest binding affinity to the
complex. Although AT-TRY shows a high increase in affinity with bis-ANS at
about 10 fold, complex association with TNS is 26 fold over initial readings, as
evident by AFmax values for the complex. The AFmax values are 618 5 7,2634

+ 46, 910 + 13 for ANS, TNS and bis-ANS respectively. Here it is important to
point out that the complex shows AFmax values higher than any other form of
serpin whereas in the ACT system the latent form had slightly higher AFmax
values in association with both ANS and TNS, than the complex. It is difficult to
pinpoint exactly why the complexes display such differences except to point out
that that the two serpin:proteinase complexes are structurally different and these
differences point to variability in exosite binding structures, where the
fluorophores may bind.

Figure 27

ANS titration of AT- Native, Cleaved, Latent
and AT:TRY complex
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Figure 28

TNS titration of AT- Native, Cleaved, Latent
and AT:TRY complex
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Figure 29

B-ANS titration of AT- Native, Cleaved, Latent
and AT:TRY complex
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Overall Results

KDvalues of the serpin variants indicate some important things. If the
ligand is unchanged while the receptor environment is varied, then the results
may be analyzed in terms of the most favorable receptor. Table 30 shows that
there seems to be no consistent pattern. ANS binds all serpin variants with
about the same affinity, as is also the case for TNS and bis-ANS. Looking down
each column where the serpin variant is kept constant and the ligand changes,
one can notice a trend. The KDvalues decrease as the ligand changes from
ANS to TNS to bis-ANS.

Figure 30. Overall KDvalues

Figure 31: Overall AFmax values
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The AFmax values are more useful. Across each row where the ligand
environment is kept constant and the receptor is variable, few patterns are
discernible. First, the cleaved form of the serpin shows the least change in
AFmax values suggesting that the hydrophobic binding pocket within this
structure does not associate well with all three ligands. Both latent and complex
forms of the serpin show consistently higher AFmax values than either the native
or cleaved. This may be interpreted as both variants associating to a higher
degree than the native and cleaved variants of the serpins, and pointing to a
binding site with greater hydrophobic character or more number of hydrophobic
sites. More importantly, differentiation between the conformational variants is
possible due to the differences in AFmax values. Within each column
conclusions are more difficult to make. On average, both bis-ANS and TNS
associate to a greater degree than ANSI due to higher AFmax values.

Modulation of Enzyme Activity

It's known that pH, concentration of ions, and temperature have an
adverse affect on enzyme activity. For example it is known that chymotrypsin

and trypsin perform optimally at pH 8.5, and at 37°C. The presence of other
molecules on enzyme activity is seen in the human body and this keeps
enzymatic activity under physiological control. The purpose of performing a
modulation study with organochemical ligands and serpin molecules is to deduce
whether these molecules affect serpin activity. If these ligands do affect activity,
then this knowledge can be used to further study the interaction. More
importantly, effects on enzyme activity may be exploited for medicinal purposes,
especially in disease states where serpin molecules are involved.
The particular study that was undertaken to check for modulation of serpin
activity by bis-ANS involved setting up the experimental procedure for generating
the latent form of serpin molecules. 100 p1 of 2 pM antichymotrypsin is allowed
to incubate with 10 pM bis-ANS. A similar sample of antichymotrypsin by itself is
incubated as a control measure. 10 p1 samples are measured at 0, 1, 3, 5, 8 and
24 hours to measure for residual chymotrypsin activity. The results of this
experiment are displayed on the following graph (figure 32). The graph shows
that there is little if any influence of bis-ANS on the activity of native
antichymotrypsin conversion to the latent form. At all the time points the residual
chymotrypsin activity of both the sample with bis-ANS and the sample wlbis-ANS
are within 5% of each other. From the results of the graph one can conclude that
bis-ANS will have an inconsequential effect on the activity of antichymotrypsin.

Figure 32
Modulation of 2 pM ACT using 10 pM B-ANS

Time (hr)

Hydrophobic Binding Domains in Serpin Conformations

After determining our results, the next step is to model the complex, and
look for potential hydrophobic pockets which may exist within the external 3dimensional structure. The following figure (33) shows the scaffold of antitrypsintrypsin complex (1EOZ), and below it is a topological surface rendering of the
complex, using SYBYL. Looking at the hydrophobic potential surface scan
(figure 34), the colors at the top or brown areas represent the most hydrophobic
potential, whereas the colors at the bottom represent hydrophilic potential. Just
from viewing the face of 50% of the molecule there are several potential pockets
where bis-ANS may bind. There are two pockets to the right of strands 1 and 2

of

0 sheet A, and to the left of helix E which are similar to pockets implicated in

vitronectin:PAl-1 potential binding.
Figure 33: 3-D structure of AT-TRY complex
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Figure 34: Hydrophobic potential map of AT-TRY complex

Chapter 5: Conclusions
Returning to our objectives we may be able to put in perspective the
results from our study. The first objective deals with differentiation of the
conformations of serpins using fluorescence spectroscopy. From the results the
first objective has been met, and this is due to the unique values for each of the
conformations when fluorophore is bound.
Both the antitrypsin and antichymotrypsin systems display some common
and unique results. Both the AT and ACT show that the TNS and bis-ANS
fluorophore are overall more sensitive in detecting the presence of both serpin
systems, while ANS is the least sensitive, and this is apparent from looking at the
AFmax values. The KDvalues do not show any consistent pattern amongst the
respective serpin systems.
In terms of unique results, bis-ANS reaction with ACT has the greatest
affinity of the three fluorophores for ACT. In particular, bis-ANS showed elevated
association to the ACT-CHY complex, while bis-ANS did not show similar results
for the AT system. For the AT system, the AT-TRY complex displayed elevated
association with TNS fluorophore. This difference in results can be exploited
through detailed study of the external structure of both complexes. ACT and AT
share 45% homology, therefore differences in complex structure are likely.

From the binding studies of the ACT system there are a few clear
conclusions. Both TNS and bis-ANS give higher AFmax values than ANS.
Concentrations used for ANS are about 10 times lower for titrations. Bis-ANS
gives significantly higher AFmax values for the ACT: CHY than the other
conformations, while also exhibiting relatively low KDvalues averaging 5 pM.
From the binding studies of the AT system a few conclusions may also be made.
Both TNS and bis-ANS also give higher AFmax values than ANS. KDvalues for
the bis-ANS titration are relatively low when compared to other dyes. Bis-ANS
has greater affinity for the AT system than does either TNS or ANS. AFmax
values for TNS titration of AT: TRY complex are significantly higher than other
structural conformers of AT.
Fluorescent dyes bind tightly to hydrophobic pockets within the protein
structure. Bis ANS displays an increase in fluorescence 36 times higher for
ACT:CHY complex than for buffer solution alone, and TNS 27 times higher for
the AT:TRY than buffer alone. With the data given, designing analogues to probe
the structure of the serpin: protease complex to determine the degree of
interaction and ability to control the kinetics of this interaction are possible.
The second objective, modulation of serpin activity by fluorophores,
showed that exposing bis-ANS to native ACT during it's conversion to latent ACT
had no significant effect on its activity. Therefore, it is concluded that
fluorophores, in particular bis-ANS, does not modulate the transition between
native and latent serpin structures.

The third objective, to determine whether there is a conserved binding site
on serpins, was addressed and reveals numerous hydrophobic pockets which
may bind small organic fluorophores such as ANS. Determining whether binding
occurs to a specific pocket might prove difficult, due to differences in serpin
structure and the large number of potential binding pockets. In order to study
this, further tests must be conducted including modeling and mapping of the
external structure of serpins.
As a final note, formation of the conformations yielded some problems.
First, the formation of latent conformation was verified using assay, and
procedure which limits polymer formation, but the possibility of polymers forming
in solution still remains. The gel electrophoresis studies show presence of the
latent confirmation, but this could just as easily be polymers, as they are known
to form from ionic bonding, which would be broken in the presence of SDS. The
second issue has to do with the results of the gel electrophoresis experiments.
Unfortunately, formation of complex was not verifiable through this method,
although procedures for complex formation were adhered to, and assay
experiments validated complex formation.
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